A Phase 2 interventional study of GA001 and Sham injection in Retinitis Pigmentosa (RP), sponsored by GenAns Biotechnology Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by GenAns Biotechnology Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Retinitis Pigmentosa with a site in China — 13 open to participants now, 14 under way, 1 of them phase 3. Retinitis Pigmentosa · China.
Among the 18 studies in Retinitis Pigmentosa with a site in China, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2027, is one of 2 in phase 2, reaches primary completion later than 12 of the 13 other live ones, and was the 18th registered.
278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.
Browse Retinitis Pigmentosa studies →13 of the 18 studies in Retinitis Pigmentosa with a site in China are open now. Recruiting first, the newest first:
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 18+
Chigenovo Co., Ltd · Sites in China
Ages 18+
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
Frontera Therapeutics · Sites in China
Ages 8–45 · Men only
Zhongmou Therapeutics · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 4 · Phase 3 1
First in 2005; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 12 is below the median of 27 across 179 interventional studies indexed under Retinitis Pigmentosa.
Median enrollment 23 across the 16 interventional studies, 2,149 across the 2 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 18 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with GenAns Biotechnology Co., Ltd as lead sponsor.
GenAns Biotechnology Co., Ltd has 1 study filed under Retinitis Pigmentosa — fewer than ten, so there is no comparison to draw.
4 of the studies in Retinitis Pigmentosa with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05805007Peking University Third HospitalSafety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa | 2026-12 |
| NCT03944239Qi ZhouSafety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa | 2026-12-31 |
| NCT07311863Suzhou UgeneX Therapeutics Co., Ltd.UGX202 Injection in Patients With Advanced Retinitis Pigmentosa | 2027-03 |
| NCT07126470Zhongshan Ophthalmic Center, Sun Yat-sen UniversityImpact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Retinitis Pigmentosa with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase II clinical trial evaluates the safety, tolerability, and efficacy of GA001 Injection in patients with retinitis pigmentosa.
Retinitis pigmentosa (RP) is an inherited retinal disease that causes gradual vision loss and can lead to blindness, with no approved curative treatment currently available.
This Phase II study is designed to evaluate the safety, tolerability, and efficacy of a single unilateral intravitreal injection of GA001 Injection at the target dose compared with sham injection in patients with retinitis pigmentosa. The study employs a sham-controlled design and will assess safety and efficacy outcomes as well as multiple functional and structural measures of visual performance over long-term follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Genetic: GA001
Procedure: Sham injection
Single unilateral IVT injection of GA001 Injection in the study eye
Sham IVT procedure in the study eye
To evaluate the efficacy of GA001 Injection in patients with retinitis pigmentosa
BCVA-Change from Baseline in LogMAR Best Corrected Visual Acuity (BCVA) BCVA assessed by ETDRS charts at each post-treatment visit compared with the sham group.baseline→W52,Unit: LogMAR MLMT-Change from Baseline in Multi-Luminance Mobility Test (MLMT) Performance MLMT 7 levels; baseline→W52 ambient Lux to finish course, vs. sham. Unit: Lux Light Sensitivity-Change from Baseline in Light Sensitivity (Minimum Identifiable Brightness) Min brightness (Lux), study eye; baseline→W52, vs. sham. Unit: Lux FST Threshold-Change from Baseline in Full-Field Stimulus Test (FST) Threshold Full-field stimulus test; baseline→W52, vs. sham. Unit: log cd·s/m² Central Visual Field-Change from Baseline in Central Visual Field Static perimetry; baseline→W52, vs. sham. Unit: dB (mean deviation) MRDQ-Change from Baseline in Michigan Retinal Degeneration Questionnaire (MRDQ) Total Score MRDQ total score; baseline→W52, vs. sham. Unit: total score (points)
Time frame: Baseline to Week 52
Incidence of Treatment-Emergent Adverse Events and serious adverse events
Incidence of severity of ocular and systemic adverse events (AEs) and serious adverse events (SAEs) following a single intravitreal injection of GA001
Time frame: Baseline to Week 52
Evaluation of the Immunogenicity of GA001 Injection after a Single Intravitreal Administration in Patients with Retinitis Pigmentosa
Immunogenicity of GA001 Injection will be evaluated following a single intravitreal injection in patients with retinitis pigmentosa, by AAV neutralizing antibody titers in peripheral blood (cell-based neutralizing assay) and by analysis of GA001-specific T-cell immune responses.
Time frame: Baseline to Week 52
Maximum Concentration (Cmax) of GA001 Vector DNA
Cmax of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.
Time frame: Baseline to Week 52
Area Under the Concentration-Time Curve (AUC) of GA001 Vector DNA
AUC of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.
Time frame: Baseline to Week 52
Time to Maximum Concentration (Tmax) of GA001 Vector DNA
Tmax of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.
Time frame: Baseline to Week 52
Biodistribution of GA001 Vector DNA
Biodistribution of GA001 vector DNA will be assessed by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.
Time frame: Baseline to Week 52
Shedding of GA001 Vector DNA
Shedding of GA001 vector DNA will be assessed by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.
Time frame: Baseline to Week 52
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2027; primary completion for Nov 2029, 31 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.